BMC Cancer
- LI J, Yang Z, Wang T, Li M, et al
Causal relationship between lipid-lowering drugs and ovarian cancer, cervical
cancer: a drug target mendelian randomization study.
BMC Cancer. 2024;24:667.
Gynecol Oncol
- BORHO L, Bao R, Elishaev E, Dinkins KD, et al
Association of allostatic load with overall survival in epithelial ovarian
cancer.
Gynecol Oncol. 2024;186:204-210.
- VALABREGA G, Pothuri B, Oaknin A, Graybill WS, et al
Efficacy and safety of niraparib in patients aged 65 years and older with
advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
Gynecol Oncol. 2024;187:128-138.
- FRANCO S, Godley LA
Myeloid neoplasms in individuals with breast and ovarian cancer and the
association with deleterious germline variants.
Gynecol Oncol. 2024;187:235-240.
- LOF P, van Soolingen NJ, Piek JMJ, Aarts JWM, et al
Preferences and considerations for interval cytoreductive surgery in advanced
ovarian cancer: The patient's perspective.
Gynecol Oncol. 2024;187:227-234.
- PITIYARACHCHI O, Ansell PJ, Coleman RL, Dinh MH, et al
Homologous recombination deficiency should be tested for in patients with
advanced stage high-grade serous ovarian cancer aged 70 years and over.
Gynecol Oncol. 2024;187:221-226.
Nat Med
- JIANG R, Feng Y, Chen Y, Cheng X, et al
Surgery versus no surgery in platinum-sensitive relapsed ovarian cancer: final
overall survival analysis of the SOC-1 randomized phase 3 trial.
Nat Med. 2024 Jun 1. doi: 10.1038/s41591-024-02981.
PLoS One
- KIM NK, Suh DH, Kim K, No JH, et al
High-throughput viable circulating tumor cell isolation using tapered-slit
membrane filter-based chipsets in the differential diagnosis of ovarian tumors.
PLoS One. 2024;19:e0304704.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016